Pseudotyping of Lentiviral Vector for Targeting Astrocytic Tumor Cells

Creative Biolabs is pleased to share our cutting-edge technology and extensive expertise in the field of viral vector development with our customers. We offer high-quality customized services by adjusting protocols to meet even the most specific requirements. We have won a good reputation among our worldwide customers for successfully accomplishing numerous challenging projects in lentiviral vector pseudotyping services.

Introduction of Astrocytic Tumor Cells

Astrocytic tumors are a series of brain tumors that are derived primarily from numerous brain cells, especially in astrocytes. Astrocytic tumors have been classified into four grades basing on different invasiveness conditions, including pilocytic astrocytomas, fibrillary astrocytomas, anaplastic astrocytomas, as well as glioblastoma multiforme. Among them, glioblastoma is the most aggressive type that has strong growth potential and can affect many tissues or organs of patients. For the treatment of astrocytic tumors, many studies suggest that gene therapy basing on lentiviral vectors should be an effective way of managing the transduction of malignant gliomas in pre-clinical studies. For example, more recent research has demonstrated that the glycoproteins of lymphocytic choriomeningitis virus (LCMV) can be used for pseudotyping of lentiviral vectors. The data suggests that it can efficiently transduce human astrocytic tumor cells. Meanwhile, lentiviral vectors targeting astrocytic tumor cells have a large gene transfer capacity. In this condition, a number of gene delivery systems have been developed in various types of animals.

Service at Creative Biolabs

Lentiviral vectors have been regarded as one of the most popular viral vectors for infecting non-dividing cells without cytotoxic or immune responses in brain tumors. Currently, Creative Biolabs has established a comprehensive platform for designing and pseudotyping of lentiviral vectors to offer perfect delivery systems for gene therapy. Nowadays, we have developed a range of pseudotyped lentiviral vectors targeting astrocytic tumor cells. Moreover, glycoproteins (GPs) from many species of viruses, such as rabies virus, vesicular stomatitis virus (VSV), and lymphocytic choriomeningitis virus (LCMV) have been widely used for vector pseudotyping. In addition, the cytotoxicity and transgene expression of lentiviral vectors have also been evaluated by our labs for gene therapy application. In the current studies, the transduction efficacy of different pseudotyped lentiviral vectors for malignant glioma cells has been compared in vitro and in vivo. LCMV-GP and VSV-GP-based pseudotyped lentiviral vectors show the effectiveness in several solid glioma cells, which provides a novel option for gene therapy of malignant glioma. Nowadays, we are focused on a wide range of viruses that may serve as potential tools for gene therapy in cancers, including but not limited to:

Equipped with our advanced technologies and platforms, Creative Biolabs now offers a panel of services to develop well-validated and highly published viral vectors with your gene-of-interest. Our mission is to help you meet current and future viral vector demand and clear the path to commercialization to help you stay at the forefront of cell and gene therapy. If you are interested in our services, please contact us for more details.